Methane (IMO) — The Quiet Cousin of SIBO

A different organism

Methane in the gut is produced not by bacteria but by archaea — chiefly Methanobrevibacter smithii. Because these are not bacteria, the term SIBO is technically imprecise; the North American Consensus now recognises IMO — Intestinal Methanogen Overgrowth.

Clinical picture

IMO strongly correlates with constipation, slowed transit, and abdominal distension. Treatment often combines rifaximin with neomycin or metronidazole, or herbal equivalents.

For years, methane-related digestive disorders were grouped under the umbrella of Small Intestinal Bacterial Overgrowth (SIBO). If a patient produced methane during a breath test, they were often told they had "methane SIBO."

Today, we know that's not entirely accurate.

In 2020, an international panel of experts introduced a new term: Intestinal Methanogen Overgrowth (IMO). The change reflected an important scientific discovery. Methane is not produced by bacteria at all—it is produced by archaea, a completely different group of microorganisms.

The distinction may seem subtle, but it changes how clinicians think about diagnosis, symptoms and treatment.

More than a name change

Unlike hydrogen-producing bacteria, methane-producing archaea belong primarily to the species Methanobrevibacter smithii. Rather than fermenting carbohydrates themselves, these organisms consume hydrogen produced by neighboring bacteria and convert it into methane.

This relationship explains why methane production often persists even after hydrogen-producing bacteria are reduced. It also helps explain why methane-positive patients frequently require a different treatment strategy than those with hydrogen-predominant SIBO.

The scientific community adopted the term Intestinal Methanogen Overgrowth because methanogens are not bacteria. While they behave similarly within the gut ecosystem, they belong to an entirely separate biological domain.

Understanding this distinction has improved both research and clinical practice.

Why methane matters

Methane is not simply an innocent byproduct of digestion.

Research consistently demonstrates that methane slows intestinal transit. In practical terms, this means food moves more slowly through the digestive tract, increasing the likelihood of constipation, bloating and abdominal distension.

Several studies have shown a direct relationship between methane production and constipation severity. In fact, higher methane levels measured during breath testing are often associated with slower intestinal transit times and more severe constipation.

For this reason, patients experiencing chronic constipation, incomplete evacuation and persistent bloating are often evaluated for methane production in addition to hydrogen.

While not every person with constipation has IMO, methane has become one of the strongest biological markers associated with constipation-predominant digestive disorders.

Hydrogen and methane often coexist

One of the more interesting discoveries in microbiome research is that methane-producing archaea depend on other microbes to survive.

Hydrogen-producing bacteria break down carbohydrates and release hydrogen gas. Methanogens then consume that hydrogen and convert it into methane.

This partnership means patients frequently have both hydrogen-producing bacterial overgrowth and methane-producing archaeal overgrowth simultaneously.

In some cases, methane can actually suppress measurable hydrogen levels during breath testing because hydrogen is rapidly consumed as methane is produced. This is one reason why modern breath tests measure both gases rather than hydrogen alone.

A normal hydrogen result does not necessarily exclude microbial overgrowth if methane production is elevated.

Diagnosis has evolved

Breath testing remains the primary non-invasive method for diagnosing IMO.

The North American Consensus defines a methane concentration of 10 parts per million (ppm) or greater at any point during the breath test as consistent with Intestinal Methanogen Overgrowth.

Unlike hydrogen, methane may already be elevated before the test solution is consumed because methanogens can remain active throughout the intestinal tract, including the colon.

Interpreting breath tests therefore requires understanding both hydrogen and methane patterns rather than focusing on a single gas.

As research advances, breath testing protocols continue to improve, giving clinicians better tools for identifying methane-predominant disease.

Treatment is different

Because methanogens are not bacteria, they often respond differently to therapy.

Research suggests that methane-positive patients frequently require combination treatment rather than therapies directed solely at hydrogen-producing bacteria. Clinicians may also focus more aggressively on improving intestinal motility, correcting constipation and reducing conditions that allow methanogens to persist.

Dietary strategies such as a temporary low FODMAP diet may help reduce symptoms by limiting fermentation, but diet alone rarely eliminates methane overgrowth.

Long-term improvement usually depends on identifying and addressing the underlying factors that allowed microbial overgrowth to develop in the first place.

The bigger picture

The introduction of Intestinal Methanogen Overgrowth was more than a change in terminology—it reflected a deeper understanding of the gut microbiome.

As researchers continue to uncover how bacteria, archaea and fungi interact inside the digestive tract, treatments are becoming increasingly targeted and personalized.

For patients, that means a more accurate diagnosis and a better chance of addressing the true cause of persistent digestive symptoms rather than simply managing them.

The takeaway

Not every case of "methane SIBO" is actually SIBO. In many cases, it is Intestinal Methanogen Overgrowth—a distinct condition driven by methane-producing archaea rather than bacteria. Recognizing that difference has changed how clinicians diagnose, interpret breath tests and approach treatment.

At The SIBO Institute, our mission is to make emerging microbiome research understandable and practical. As new discoveries reshape our understanding of digestive health, we're committed to providing evidence-based articles, clinical updates and educational guides to help patients navigate their path toward recovery.

References Pimentel M, et al. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. 2020. https://pubmed.ncbi.nlm.nih.gov/32023228/ Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. 2017. https://pubmed.ncbi.nlm.nih.gov/28323273/ Pimentel M, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. American Journal of Physiology. 2006. https://pubmed.ncbi.nlm.nih.gov/16611747/ Triantafyllou K, Chang C, Pimentel M. Methanogens, Methane and Gastrointestinal Motility. Journal of Neurogastroenterology and Motility. https://www.jnmjournal.org/ American College of Gastroenterology. Small Intestinal Bacterial Overgrowth Clinical Guideline. https://gi.org/guideline/small-intestinal-bacterial-overgrowth/